1. acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or presenting symptoms suggestive of covid-19 within the previous 28 days, or having been in contact with an infected individual for the last 10 days before the inclusion visit; 2. virologically documented history of covid-19 (pcr or serology); 3. immunosuppressive therapy such as corticosteroids \> 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies; 4. treatment with immunoglobulins or other blood derivatives within 3 months prior to inclusion or scheduled administration of immunoglobulins or blood derivatives before the end of the study; 5. known hiv, hcv or hbv infection; 6. any medical condition, such as cancer, that might impair the immune response; 7. use of experimental immunoglobulins, experimental monoclonal antibodies or convalescent plasma is not permitted during the study; 8. pregnancy or breastfeeding currently ongoing; 9. history of severe adverse events following vaccine administration including anaphylactic reaction and associated symptoms such as rash, breathing problems, angioedema, and abdominal pain, or a history of allergic reaction that could be triggered by a component of the sars-cov-2 vaccine at the time of the first vaccine injection; 10. participant who has received bcg (tuberculosis) vaccine within the previous year; 11. has received a vaccine within 4 weeks prior to the boost injection or is scheduled to receive a registered vaccine 4 weeks after the boost injection 12. any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy, or receipt of anticoagulants 13. participation in other research involving humans (french classification jarde 1 or jarde 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial 14. subject under legal protection (e.g. guardianship, tutorship)

1. acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or presenting symptoms suggestive of covid-19 within the previous 28 days, or having been in contact with an infected individual for the last 10 days before the inclusion visit; 2. virologically documented history of covid-19 (pcr or serology); 3. immunosuppressive therapy such as corticosteroids \> 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies; 4. treatment with immunoglobulins or other blood derivatives within 3 months prior to inclusion or scheduled administration of immunoglobulins or blood derivatives before the end of the study; 5. known hiv, hcv or hbv infection; 6. any medical condition, such as cancer, that might impair the immune response; 7. use of experimental immunoglobulins, experimental monoclonal antibodies or convalescent plasma is not permitted during the study; 8. pregnancy or breastfeeding currently ongoing; 9. history of severe adverse events following vaccine administration including anaphylactic reaction and associated symptoms such as rash, breathing problems, angioedema, and abdominal pain, or a history of allergic reaction that could be triggered by a component of the sars-cov-2 vaccine at the time of the first vaccine injection; 10. participant who has received bcg (tuberculosis) vaccine within the previous year; 11. has received a vaccine within 4 weeks prior to the boost injection or is scheduled to receive a registered vaccine 4 weeks after the boost injection 12. any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy, or receipt of anticoagulants 13. participation in other research involving humans (french classification jarde 1 or jarde 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial 14. subject under legal protection (e.g. guardianship, tutorship)

acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or presenting symptoms suggestive of covid-19 within the previous 28 days, or having been in contact with an infected individual for the last 14 days before the inclusion visit; virologically documented history of covid-19 (pcr or serology); immunosuppressive therapy such as corticosteroids > 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies; treatment with immunoglobulins or other blood derivatives within 3 months prior to inclusion or scheduled administration of immunoglobulins or blood derivatives before the end of the study; known hiv, hcv or hbv infection; any medical condition, such as cancer, that might impair the immune response; use of experimental immunoglobulins, experimental monoclonal antibodies or convalescent plasma is not permitted during the study; pregnancy or breastfeeding currently ongoing; history of severe adverse events following vaccine administration including anaphylactic reaction and associated symptoms such as rash, breathing problems, angioedema, and abdominal pain, or a history of allergic reaction that could be triggered by a component of the sars-cov-2 vaccine at the time of the first vaccine injection; participant who has received bcg (tuberculosis) vaccine within the previous year; has received a vaccine within 4 weeks prior to the boost injection or is scheduled to receive a registered vaccine 4 weeks after the boost injection any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy, or receipt of anticoagulants participation in other research involving humans (french classification jarde 1 or jarde 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial subject under legal protection (e.g. guardianship, tutorship)

acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or presenting symptoms suggestive of covid-19 within the previous 28 days, or having been in contact with an infected individual for the last 14 days before the inclusion visit; virologically documented history of covid-19 (pcr or serology); immunosuppressive therapy such as corticosteroids > 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies; treatment with immunoglobulins or other blood derivatives within 3 months prior to inclusion or scheduled administration of immunoglobulins or blood derivatives before the end of the study; known hiv, hcv or hbv infection; any medical condition, such as cancer, that might impair the immune response; use of experimental immunoglobulins, experimental monoclonal antibodies or convalescent plasma is not permitted during the study; pregnancy or breastfeeding currently ongoing; history of severe adverse events following vaccine administration including anaphylactic reaction and associated symptoms such as rash, breathing problems, angioedema, and abdominal pain, or a history of allergic reaction that could be triggered by a component of the sars-cov-2 vaccine at the time of the first vaccine injection; participant who has received bcg (tuberculosis) vaccine within the previous year; has received a vaccine within 4 weeks prior to the boost injection or is scheduled to receive a registered vaccine 4 weeks after the boost injection any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy, or receipt of anticoagulants participation in other research involving humans (french classification jarde 1 or jarde 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial subject under legal protection (e.g. guardianship, tutorship)

acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or presenting symptoms suggestive of covid-19 within the previous 28 days, or having been in contact with an infected individual for the last 14 days before the inclusion visit; virologically documented history of covid-19 (pcr or serology); immunosuppressive therapy such as corticosteroids > 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies; treatment with immunoglobulins or other blood derivatives within 3 months prior to inclusion or scheduled administration of immunoglobulins or blood derivatives before the end of the study; known hiv, hcv or hbv infection; any medical condition, such as cancer, that might impair the immune response; use of experimental immunoglobulins, experimental monoclonal antibodies or convalescent plasma is not permitted during the study; pregnancy or breastfeeding currently ongoing; history of severe adverse events following vaccine administration including anaphylactic reaction and associated symptoms such as rash, breathing problems, angioedema, and abdominal pain, or a history of allergic reaction that could be triggered by a component of the sars-cov-2 vaccine at the time of the first vaccine injection; participant who has received bcg (tuberculosis) vaccine within the previous year; has received a vaccine within 4 weeks prior to the boost injection or is scheduled to receive a registered vaccine 4 weeks after the boost injection any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy, or receipt of anticoagulants participation in other research involving humans (french classification jardé 1 or jardé 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial subject under legal protection (e.g. guardianship, tutorship)

acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or presenting symptoms suggestive of covid-19 within the previous 28 days, or having been in contact with an infected individual for the last 14 days before the inclusion visit; virologically documented history of covid-19 (pcr or serology); immunosuppressive therapy such as corticosteroids > 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies; treatment with immunoglobulins or other blood derivatives within 3 months prior to inclusion or scheduled administration of immunoglobulins or blood derivatives before the end of the study; known hiv, hcv or hbv infection; any medical condition, such as cancer, that might impair the immune response; use of experimental immunoglobulins, experimental monoclonal antibodies or convalescent plasma is not permitted during the study; pregnancy or breastfeeding currently ongoing; history of severe adverse events following vaccine administration including anaphylactic reaction and associated symptoms such as rash, breathing problems, angioedema, and abdominal pain, or a history of allergic reaction that could be triggered by a component of the sars-cov-2 vaccine at the time of the first vaccine injection; participant who has received bcg (tuberculosis) vaccine within the previous year; has received a vaccine within 4 weeks prior to the boost injection or is scheduled to receive a registered vaccine 4 weeks after the boost injection any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy, or receipt of anticoagulants participation in other research involving humans (french classification jardé 1 or jardé 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial subject under legal protection (e.g. guardianship, tutorship)